1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Next-Gen Pneumococcal Vaccine Race Continues With Merck’s V114 Data

 
• By Mandy Jackson

Merck’s V114 protected against all 15 targeted serotypes in the first two of 16 Phase III studies, but market leader Pfizer’s 20-valent Prevnar 13 successor is on track for a US FDA filing in late 2020.

Evening scene asphalt international race track with starting or end line, digital imaging recomposition background.
Merck is in a race against Pfizer to file a new pneumococcal vaccine

Merck & Co. Inc. and Pfizer Inc. both have next-generation pneumococcal conjugate vaccines that they are in discussions about filing with regulators and now both companies have reported initial Phase III results for their programs. Merck said on 22 June that its candidate V114 was effective against all 15 pneumococcal serotypes that it was designed to address – two more than in Pfizer’s blockbuster Prevnar 13 – in adults with HIV and older adults who also received a flu vaccine.

Merck is conducting 16 Phase III clinical trials of V114, including two pivotal trials enrolling adults aged 50 and older...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 
• By Alaric DeArment

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

Moderna Posts Phase III Efficacy Data For Flu Vaccine

 
• By Joseph Haas

With positive relative efficacy data for its mRNA seasonal flu shot, Moderna hopes to file mRNA-1010 for US approval and refile a COVID-19/flu combo shot that it withdrew in May.

More from Therapy Areas

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By Joseph Haas

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 
• By Andrew McConaghie

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.